CN103222984A - 泊洛沙姆用于预防和/或治疗心力衰竭的用途 - Google Patents

泊洛沙姆用于预防和/或治疗心力衰竭的用途 Download PDF

Info

Publication number
CN103222984A
CN103222984A CN2013100791323A CN201310079132A CN103222984A CN 103222984 A CN103222984 A CN 103222984A CN 2013100791323 A CN2013100791323 A CN 2013100791323A CN 201310079132 A CN201310079132 A CN 201310079132A CN 103222984 A CN103222984 A CN 103222984A
Authority
CN
China
Prior art keywords
poloxamer
heart failure
patient
heart
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2013100791323A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁斯.E.马克哈姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phrixus Pharmaceuticals Inc
Original Assignee
Phrixus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Phrixus Pharmaceuticals Inc filed Critical Phrixus Pharmaceuticals Inc
Publication of CN103222984A publication Critical patent/CN103222984A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2013100791323A 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途 Pending CN103222984A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83472806P 2006-08-01 2006-08-01
US60/834,728 2006-08-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2007800367818A Division CN101534843A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途

Publications (1)

Publication Number Publication Date
CN103222984A true CN103222984A (zh) 2013-07-31

Family

ID=38805633

Family Applications (4)

Application Number Title Priority Date Filing Date
CN2013100791323A Pending CN103222984A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2011100477182A Pending CN102218077A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2013101207279A Pending CN103271935A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CNA2007800367818A Pending CN101534843A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN2011100477182A Pending CN102218077A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CN2013101207279A Pending CN103271935A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途
CNA2007800367818A Pending CN101534843A (zh) 2006-08-01 2007-08-01 泊洛沙姆用于预防和/或治疗心力衰竭的用途

Country Status (7)

Country Link
US (1) US9155758B2 (https=)
EP (1) EP2046348B1 (https=)
JP (2) JP5537152B2 (https=)
CN (4) CN103222984A (https=)
AU (1) AU2007281531B2 (https=)
CA (1) CA2659909A1 (https=)
WO (1) WO2008016640A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111973623A (zh) * 2020-08-06 2020-11-24 温州医科大学 心力衰竭靶向治疗的速释制剂

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2046348B1 (en) 2006-08-01 2015-07-22 Phrixus Pharmaceuticals, Incorporated Use of poloxamer for the prevention and/or treatment of heart failure
WO2008124088A2 (en) * 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
US20130143804A1 (en) * 2010-06-07 2013-06-06 Trustees Of The University Of Pennsylvania Islet Amyloid Polypeptide Toxic Oligomer is a Biomarker of Heart or Kidney Failure in Type-2 Diabetes Mellitus
EP3057598A1 (en) * 2013-10-16 2016-08-24 Mast Therapeutics, Inc. Diuretic induced alterations of plasma volume
US9757411B2 (en) 2014-07-07 2017-09-12 Aires Pharmaceuticals, Inc. Poloxamer therapy for heart failure
JP6747748B2 (ja) 2014-07-07 2020-08-26 ライフラフト バイオサイエンシーズ，インコーポレイテッド 長期循環物質のないポロクサマー組成物、その産生方法およびその使用
WO2016007542A1 (en) * 2014-07-07 2016-01-14 Mast Therapeutics, Inc. Poloxamer therapy for heart failure
US20230190676A1 (en) * 2020-07-09 2023-06-22 Musc Foundation For Research Development Methods of protecting cells from insults

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091941A2 (en) * 2005-02-25 2006-08-31 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198211A (en) 1986-05-15 1993-03-30 Emory University Method of treating myocardial damage
US5733572A (en) 1989-12-22 1998-03-31 Imarx Pharmaceutical Corp. Gas and gaseous precursor filled microspheres as topical and subcutaneous delivery vehicles
ES2140408T3 (es) 1991-03-19 2000-03-01 Cytrx Corp Copolimeros de polioxipropileno/polioxietileno con actividad biologica mejorada.
JPH05178760A (ja) 1991-06-03 1993-07-20 Alpha Therapeutic Corp 心筋梗塞治療剤
US5605687A (en) 1992-05-15 1997-02-25 Arch Development Corporation Methods and compositions of a polymer (poloxamer) for repair of electrical injury
US5994348A (en) 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
WO2000021543A1 (en) 1998-10-09 2000-04-20 Cytrx Corporation Method and composition for treating ischemia and sickle cell anemia
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6761824B2 (en) 2000-08-17 2004-07-13 Reeve Lorraine E Process for the fractionation of polymers
WO2002065834A2 (en) 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol
WO2003078603A2 (en) 2002-03-15 2003-09-25 Board Of Regents, The University Of Texas System Strong gene sets for glioma classification
US7550155B2 (en) 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
AU2005289520A1 (en) 2004-09-27 2006-04-06 Vical Incorporated Formulations and methods for treatment of inflammatory diseases
EP1809272A4 (en) 2004-10-18 2008-01-02 Maroon Biotech Corp METHOD AND COMPOSITIONS FOR TREATING DAMAGES THROUGH FREE RADICALS
DE602006014514D1 (https=) 2005-03-21 2010-07-08 Santhera Pharmaceuticals Ch
NZ569396A (en) 2006-02-03 2011-06-30 Nicox Sa Use of nitrooxyderivative of drug for the treatment of muscular dystrophies
EP2046348B1 (en) 2006-08-01 2015-07-22 Phrixus Pharmaceuticals, Incorporated Use of poloxamer for the prevention and/or treatment of heart failure
WO2008124088A2 (en) 2007-04-05 2008-10-16 Phrixus Pharmaceuticals, Inc. Compositions and methods for the treatment of heart failure
WO2009078978A2 (en) 2007-12-14 2009-06-25 Phrixus Pharmaceuticals, Inc. Compositions containing polyglycidol-based polymers and uses thereof
US8852568B2 (en) 2007-12-17 2014-10-07 The Regents Of The University Of Michigan Compositions and methods for treating and preventing skeletal muscle deficiencies
WO2011066201A2 (en) 2009-11-25 2011-06-03 The Regents Of The University Of Michigan Methods and systems for treating and preventing cardiac injury in dystrophic subjects

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091941A2 (en) * 2005-02-25 2006-08-31 The Regents Of The University Of Michigan Compositions and methods for treating and preventing cardiomyopathy and heart disease

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YASUDA SOICHIRO ET AL: "Dystrophic heart failure blocked by membrane sealant poloxamer", 《NATURE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111973623A (zh) * 2020-08-06 2020-11-24 温州医科大学 心力衰竭靶向治疗的速释制剂

Also Published As

Publication number Publication date
US20090246162A1 (en) 2009-10-01
CN102218077A (zh) 2011-10-19
EP2046348B1 (en) 2015-07-22
WO2008016640A2 (en) 2008-02-07
CN101534843A (zh) 2009-09-16
JP5537152B2 (ja) 2014-07-02
JP2013253103A (ja) 2013-12-19
JP2009545595A (ja) 2009-12-24
CN103271935A (zh) 2013-09-04
EP2046348A2 (en) 2009-04-15
AU2007281531A1 (en) 2008-02-07
AU2007281531B2 (en) 2013-07-04
US9155758B2 (en) 2015-10-13
CA2659909A1 (en) 2008-02-07
WO2008016640A3 (en) 2009-02-05

Similar Documents

Publication Publication Date Title
CN103222984A (zh) 泊洛沙姆用于预防和/或治疗心力衰竭的用途
Ezekowitz et al. Rationale and design of RE-LY: randomized evaluation of long-term anticoagulant therapy, warfarin, compared with dabigatran
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
RU2518745C2 (ru) Доставка октреотида из сухих лекарственных форм
US20090176772A1 (en) Method of reversing left ventricular remodeling
US20110044935A1 (en) Compositions and methods for treating and preventing cardiomyopathy and heart disease
US20130129662A1 (en) Compositions and Methods for the Treatment of Heart Failure
Kasama et al. Effects of perindopril on cardiac sympathetic nerve activity in patients with congestive heart failure: comparison with enalapril
SG190711A1 (en) Use of dronedarone for the preparation of a drug for use in the management of the risk of liver injury
Lee et al. New developments in clinically relevant mechanisms and treatment of hyperuricemia
WO2023205183A1 (en) Istaroxime-containing intravenous formulation for the treatment of pre-cardiogenic shock and cardiogenic shock
CN102427821A (zh) 治疗出血的组合物和方法
US20220296680A1 (en) Treatment and prevention of cardiorenal damage
WO2001078764A1 (en) Treatment of hypertrophic cardiomyopathy with a substance that increases the level of growth hormone receptor antagonists

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20130731